Scilex Holding Company (SCLXW)
SCLXW Stock Price Chart
Explore Scilex Holding Company interactive price chart. Choose custom timeframes to analyze SCLXW price movements and trends.
SCLXW Company Profile
Discover essential business fundamentals and corporate details for Scilex Holding Company (SCLXW) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
—
Employees
115.00
Website
https://www.scilexholding.comCEO
Jaisim Shah
Description
Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid therapies for patients with acute and chronic pain. The company's principal product includes ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102 or SEMDEXA, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase 3 clinical trial to treat lumbosacral radicular pain; SP-103 for the treatment of low back pain, which is in Phase 2 clinical trails; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia that is in Phase 1 clinical trials. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.
SCLXW Financial Timeline
Browse a chronological timeline of Scilex Holding Company corporate events including earnings releases, dividend announcements, and stock splits.
Earnings released on 29 Apr 2025
EPS came in at -$0.04 , while revenue for the quarter reached $14.90M .
SCLXW Stock Performance
Access detailed SCLXW performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.